Avadel Pharmaceuticals (AVDL)
NASDAQ: AVDL
· Real-Time Price · USD
9.46
0.28 (3.05%)
At close: Jun 23, 2025, 3:47 PM
3.05% (1D)
Bid | 6.81 |
Market Cap | 915.63M |
Revenue (ttm) | 194.45M |
Net Income (ttm) | -26.41M |
EPS (ttm) | -0.26 |
PE Ratio (ttm) | -36.4 |
Forward PE | 12.1 |
Analyst | Buy |
Ask | 11.75 |
Volume | 816,656 |
Avg. Volume (20D) | 1,335,020 |
Open | 9.17 |
Previous Close | 9.18 |
Day's Range | 9.07 - 9.57 |
52-Week Range | 6.38 - 17.30 |
Beta | 1.45 |
About AVDL
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AVDL
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AVDL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Avadel Pharmaceuticals is scheduled to release its earnings on Aug 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+9.61%
Avadel Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
5 months ago
-1.57%
Avadel Pharmaceuticals shares are trading lower after the company announced it sees preliminary Q4 revenues below estimates and issued FY25 net product revenue below estimates.

1 month ago · seekingalpha.com
Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'Avadel Pharmaceuticals is gaining momentum with strong Q1 results, a key legal win, and moving swiftly to profitability. LUMRYZ, Avadel's once-daily sodium oxybate, is growing rapidly and could enter ...

1 month ago · seekingalpha.com
Avadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call TranscriptAvadel Pharmaceuticals plc (NASDAQ:AVDL ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Austin Murtagh - IR Greg Divis - CEO Tom McHugh - CFO Conference Call Participant...